Compositions and methods for treating CNS disorders
Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g. in the treatment of CNS-related disorders.
1. A compound of Formula (II-IIwa), (II-IIwb), or (II-IIwc)
or a pharmaceutically acceptable salt thereof, wherein
m is 0, 1, 2, or 3;
p is 0, 1, or 2; and
each R 32 is independently halogen, C 1-6 alkyl, hydroxyl, or cyano.
2. The compound or pharmaceutically acceptable salt of claim 1 , wherein m is 1, and p is 1.
3. A compound selected from
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 1 or claim 3 , and a pharmaceutically acceptable excipient.
5. A method for treating a CNS-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1 or claim 3 , wherein the CNS-related disorder is a sleep disorder, a mood disorder, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, tinnitus, or status epilepticus.
6. The method of claim 5 , wherein the CNS-related disorder is a mood disorder, and wherein the mood disorder is depression.
7. The method of claim 6 , wherein the depression is postpartum depression or a major depressive disorder.
8. The method of claim 7 , wherein the major depressive disorder is a moderate major depressive disorder or a severe major depressive disorder.
9. The method of claim 5 , wherein the CNS-related disorder is a movement disorder, and wherein the movement disorder is seizure or tremor.
10. The method of claim 9 , wherein the tremor is essential tremor.
11. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (II-IIwa), (II-IIwb), or (II-IIwc) is a compound of Formula (II-IIwa):
or a pharmaceutically acceptable salt thereof.
12. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (II-IIwa), (II-IIwb), or (II-IIwc) is a compound of Formula (II-IIwb):
or a pharmaceutically acceptable salt thereof.
13. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (II-IIwa), (II-IIwb), or (II-IIwc) is a compound of Formula (II-IIwc):
or a pharmaceutically acceptable salt thereof.